Abstract
BACKGROUND: Alopecia areata (AA) is an autoimmune-mediated, non-scarring hair loss disorder. With the advancement of alopecia treatment research, the efficacy of Janus kinase (JAK) inhibitors in the clinical management of AA has been increasingly evaluated. OBJECTIVE: This study reports the efficacy and safety of tofacitinib in the treatment of severe AA and presents a literature review on tofacitinib in AA. METHODS: Collect patient information on severe AA treated at a tertiary hospital from April 2023 to May 2024, and analyze their clinical treatment outcomes. RESULTS: All five collected patients met the criteria for refractory alopecia areata. Three of these patients achieved favorable therapeutic outcomes with mild adverse reactions, consistent with current research findings. CONCLUSION: This study supports the efficacy and safety of tofacitinib in AA treatment, providing further clinical evidence for its application.